|
Daily Medical Update
Bipolar disorder
Thursday, April 09, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Psychopharmacology bulletin (2026) - Meta-Analysis
Key Findings
- Asenapine reduced YMRS scores vs placebo by 4.00 points (95% CI -5.55 to -2.45) across 5 trials.
- CGI-BP-S overall severity improved by 0.51 points and mania scores improved by 0.47 points vs placebo, with a modest MADRS reduction of 1.38 points.
- Adverse events increased with asenapine vs placebo, despite overall short-term efficacy.
📋 Practice Implication: Use asenapine as an evidence-based option for acute mania when rapid symptom control is needed, while monitoring tolerability because adverse events were more frequent than with placebo.
|
Bipolar disorders (2026) - Meta-Analysis
Key Findings
- Collaborative Chronic Care Models improved overall mental health outcomes (SMD = 0.28, 95% CI 0.13-0.43; p < 0.01).
- Mania symptoms improved (SMD = 0.16, 95% CI 0.01-0.30; p = 0.03) and mental health-related quality of life improved (SMD = 0.24, 95% CI 0.08-0.41; p < 0.01).
- Depression, physical health-related quality of life, and costs did not improve vs comparison care.
📋 Practice Implication: For patients with recurrent utilization or fragmented care, prioritize collaborative chronic care elements to improve overall mental health and quality of life rather than expecting clear antidepressant or cost benefits.
|
European journal of medical research (2025) - Meta-Analysis
Key Findings
- Bilateral rTMS did not improve response vs unilateral rTMS (RR 1.20, 95% CI 0.83-1.72) or remission vs unilateral rTMS (RR 1.36, 95% CI 0.87-2.12).
- Bilateral rTMS improved response vs sham (RR 2.69, 95% CI 1.58-4.57; p = 0.0003) and remission vs sham (RR 3.84, 95% CI 1.62-9.07; p = 0.002).
- Adverse events and treatment discontinuation did not increase vs unilateral or sham stimulation.
📋 Practice Implication: Reserve bilateral rTMS as a reasonable adjunct for bipolar depression when sham-level benefit is insufficient or unilateral rTMS has not delivered enough benefit, not as a proven superior first choice over unilateral protocols.
|
Psychological medicine (2026) - Meta-Analysis
Key Findings
- Across 1,021 VBM experiments, bipolar disorder showed gray matter reduction in the right middle temporal gyrus with P >= 95% selectivity.
- The bipolar-specific reduction remained robust in fail-safe analyses, whereas no selective findings were observed after adding neurological diseases to the comparison set.
📋 Practice Implication: Treat this as supportive differential-diagnostic evidence for complex mood-versus-psychotic presentations rather than a routine stand-alone imaging biomarker.
|
European psychiatry : the journal of the Association of European Psychiatrists (2026) - Meta-Analysis
Key Findings
- Vs healthy controls, bipolar disorder showed higher NLR (SMD = 0.44, p < 0.001) and MLR (SMD = 0.28, p < 0.001).
- During mania, NLR, MLR, and PLR all increased vs healthy controls, while mania also showed higher NLR and MLR vs major depressive disorder.
- Compared with depression, mania showed increased NLR, MLR, and PLR, but the overall ratios showed limited discrimination between bipolar and unipolar depression.
📋 Practice Implication: CBC-derived inflammatory ratios may help contextualize mood-state burden at the population level, but their limited specificity means they should not be used alone to distinguish bipolar from unipolar depression.
|
|
Recent meta-analyses in bipolar disorder support short-term symptom improvement with asenapine for acute mania, benefit from collaborative chronic care models, and antidepressant efficacy of bilateral rTMS versus sham, although bilateral stimulation has not clearly outperformed unilateral rTMS. Parallel biomarker and neuroimaging syntheses show reproducible group-level inflammatory and structural abnormalities, but these signals remain better suited to risk stratification and diagnostic support than to standalone clinical decision-making.
|
|